Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Riled investors look for big changes at GSK
The natives are restless and ready for a butchering. Inspired by lackluster stock performance, GlaxoSmithKline's institutional shareholders are demanding big changes--perhaps even a break-up of the company-- according to London newspapers.
The investors aren't happy about the company's performance since a 2000 merger between Glaxo and SmithKline, and they're questioning whether the enormous company is nimble enough to develop new medicines. They want Glaxo Chairman Sir Christopher Gent to choose a radical successor to CEO Jean-Pierre Garnier, who's set to retire in May 2008--and for that successor to consider any and all options to streamline and overhaul the company.
A big source of fuel for the investors' fire has to be a report released by Citigroup earlier this year, which suggested breaking up Glaxo could return some $20 billion to shareholders.
- read the article on GSK from The Guardian
Related Articles:
GSK inks $1.5B dollar pain deal with Targacept. Report
GSK sees success with RLS campaign. Report
Be the first to comment
More stories about GlaxoSmithKline
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
